Skip to Main

Daniel Schroer is a member of Boston Consulting Group’s Health Care and Technology Advantage practices and a topic expert for medical technology.

Since joining BCG in 2006, Daniel has worked with numerous major health care and medtech companies on issues related to corporate strategy and new commercial models, mergers and acquisitions, and go-to-market strategy, as well as many sales, marketing, and pricing excellence projects.

Daniel has extensive experience in digital business models and leads BCG's digital business in medical technology worldwide.

Before joining BCG, Daniel was a research assistant at the Fraunhofer Institutes and worked as an intern for Arthur D. Little, DaimlerChrysler, Bayer, and BRAINnet.

AREAS OF EXPERTISE

EDUCATION

  • Master’s degree, industrial engineering and management, Karlsruhe Institute of Technology

Publications and Videos

" "

Medtech Companies Must Move Faster on Generative AI

To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
" "

Medtech’s Generative AI Opportunity

The technology has a range of uses in medtech, and the main challenge is knowing how and where to start. Here are 60 ways to generate quick wins.
full-potential-plans-2880x1620-tcm9-213775.jpg

How Full-Potential Plans Help PE-Owned Companies Outperform in Medtech

A much more rigorous approach to value creation lets investor-held medtech firms win in the face of price erosion and other challenges.
why-every-medtech-company-2880x1620-tcm9-173990.jpg

Why Every Medtech Company Needs a Value-Based Strategy

Some medtech CEOs have embraced value-based health care and the business opportunity it represents, but many remain cautious. That’s understandable—but strategically misguided. Companies don’t have the luxury to wait.